Journal
MEDICINAL RESEARCH REVIEWS
Volume 21, Issue 5, Pages 356-381Publisher
JOHN WILEY & SONS INC
DOI: 10.1002/med.1014
Keywords
vancomycin; teicoplanin; ramoplanin; synthesis
Categories
Funding
- NCI NIH HHS [CA 41101] Funding Source: Medline
Ask authors/readers for more resources
Vancomycin, teicoplanin, and ramoplanin are potent glycopeptide antibiotics that act by inhibiting bacterial cell wall biosynthesis. The former are used clinically as the antibiotics of last resort for the treatment of methicillin-resistant Staphylococcus aureus and the latter is a promising new antibiotic that is not susceptible to the emerging bacterial resistance to vancomycin and teicoplanin. A summary of our recent total synthesis of the vancomycin aglycon, our first and second generation total syntheses of the teicoplanin aglycon, and our progress on the total synthesis of the ramoplanins is presented. This work lays the foundation for ongoing structure-function studies on the antibiotics that may clarify or define their site and mechanism of action leading to the development of improved or reengineered antibiotics. (C) 2001 John Wiley & Sons, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available